Production (Stage)
Zenas BioPharma, Inc.
ZBIO
$11.43
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -255.16% | -322.87% | -309.03% | -- | -- |
| Total Depreciation and Amortization | 7.63% | 21.24% | 24.07% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.91% | -19.11% | -39.50% | -- | -- |
| Change in Net Operating Assets | 44.94% | 416.35% | 268.03% | -- | -- |
| Cash from Operations | -483.94% | -292.00% | -199.23% | -- | -- |
| Capital Expenditure | -225.64% | -670.59% | 0.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -2,576.00% | -- | -- |
| Cash from Investing | -299,397.44% | -179,617.65% | -2,398.51% | -- | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 233,849.51% | 207,581.90% | 355,407.58% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 200.35% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -765.55% | -- | -- | -- | -- |
| Cash from Financing | 2,027.17% | 1,952.88% | 417.46% | -- | -- |
| Foreign Exchange rate Adjustments | -42.02% | 101.28% | -138.80% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,042.42% | 2,639.50% | 521.31% | -- | -- |